Table 1.
The effect of tocomin, α-tocopherol (TC), and α-, δ-, and γ-tocotrienols (T3) on ACh-induced endothelium-dependent and SNP-induced endothelium-independent relaxation of rat aortae in the presence of pyrogallol-induced oxidative stress.
| n | ACh | SNP | |||
|---|---|---|---|---|---|
| pEC50 (M) | R max (%) | pEC50 (M) | R max (%) | ||
| α-tocopherol | |||||
| Control | 5–7 | −7.09 ± 0.18 | 95 ± 8 | −8.71 ± 0.10 | 108 ± 7 |
| Pyrogallol | 5–7 | −7.13 ± 0.18 | 47 ± 4# | −8.46 ± 0.14 | 97 ± 5 |
| Pyrogallol + α-TC 10−4 mg/mL | 5–7 | −6.52 ± 0.21 | 47 ± 5# | −8.55 ± 0.12 | 94 ± 4 |
| Pyrogallol + α-TC 10−3 mg/mL | 5–7 | −6.84 ± 0.12 | 46 ± 8# | −8.35 ± 0.28 | 96 ± 5 |
| Pyrogallol + α-TC 10−2 mg/mL | 5–7 | −6.97 ± 0.15 | 70 ± 2∗ | −8.57 ± 0.42 | 90 ± 5 |
| α-tocotrienol | |||||
| Control | 3–6 | −7.08 ± 0.16 | 86 ± 10 | −8.58 ± 0.25 | 97 ± 3 |
| Pyrogallol | 3–6 | −6.97 ± 0.15 | 51 ± 2# | −8.67 ± 0.25 | 96 ± 7 |
| Pyrogallol + α-T3 10−3 mg/mL | 3–6 | −6.25 ± 0.22 | 47 ± 4# | −8.41 ± 0.26 | 105 ± 4 |
| Pyrogallol + α-T3 10−2 mg/mL | 3–6 | −6.58 ± 0.16 | 45 ± 5# | −8.40 ± 0.09 | 94 ± 7 |
| Pyrogallol + α-T3 10−1 mg/mL | 3–6 | −6.82 ± 0.23 | 58 ± 5# | −8.12 ± 0.02 | 105 ± 4 |
| δ-tocotrienol | |||||
| Control | 3–6 | −6.98 ± 0.12 | 80 ± 3 | −8.38 ± 0.28 | 97 ± 4 |
| Pyrogallol | 3–6 | −6.83 ± 0.45 | 42 ± 10# | −8.49 ± 0.20 | 99 ± 3 |
| Pyrogallol + δ-T3 10−3 mg/mL | 3–6 | −6.74 ± 0.08 | 46 ± 9# | −8.73 ± 0.07 | 98 ± 2 |
| Pyrogallol + δ-T3 10−2 mg/mL | 3–6 | −6.75 ± 0.29 | 43 ± 8# | −8.51 ± 0.05 | 95 ± 8 |
| Pyrogallol + δ-T3 10−1 mg/mL | 3–6 | −6.64 ± 0.30 | 46 ± 8# | −8.60 ± 0.20 | 99 ± 2 |
| γ-tocotrienol | |||||
| Control | 3–6 | −6.71 ± 0.24 | 93 ± 4 | −8.50 ± 0.80 | 93 ± 4 |
| Pyrogallol | 3–6 | −6.51 ± 0.15 | 59 ± 4# | −8.45 ± 0.20 | 98 ± 2 |
| Pyrogallol + γ-T3 10−3 mg/mL | 3–6 | −6.16 ± 0.17 | 53 ± 4# | −8.34 ± 0.12 | 103 ± 1 |
| Pyrogallol + γ-T3 10−2 mg/mL | 3–6 | −6.71 ± 0.27 | 55 ± 7# | −8.59 ± 0.15 | 95 ± 4 |
| Pyrogallol + γ-T3 10−1 mg/mL | 3–6 | −6.65 ± 0.22 | 67 ± 1# | −8.68 ± 0.25 | 97 ± 1 |
| Tocomin | |||||
| Control | 5–7 | −7.19 ± 0.08 | 92 ± 3 | −8.69 ± 0.18 | 97 ± 4 |
| Pyrogallol | 5–7 | −7.06 ± 0.13 | 58 ± 5# | −8.25 ± 0.05 | 99 ± 2 |
| Pyrogallol + tocomin 10−6 mg/mL | 5–7 | −6.84 ± 0.14 | 63 ± 6# | −8.14 ± 0.24 | 100 ± 7 |
| Pyrogallol + tocomin 10−5 mg/mL | 5–7 | −6.94 ± 0.13 | 69 ± 5# | −8.23 ± 0.18 | 103 ± 4 |
| Pyrogallol + tocomin 10−4 mg/mL | 5–7 | −6.70 ± 0.20 | 81 ± 2∗ | −8.17 ± 0.14 | 99 ± 2 |
#Significantly different to control p < 0.05.
∗Significantly different to pyrogallol p < 0.05.
Sidak's multiple comparison test.